Copyright © 2013, The Oklahoma Publishing Company
Oklahoma City-based Sensulin, LLC, a diabetes-focused biopharmaceutical company, received the 2013 Michael E. DeBakey Life Science Award at the recent second annual Texas Life Science Venture Forum in Houston.
The DeBakey award is presented to the “undiscovered life science company with the highest potential to commercialize an important product.”
Sensulin also received the Rice Alliance Most Promising Life Science Technology at the Houston event.
Sensulin is developing a 24-hour glucose responsive insulin that would provide a patient’s entire daily need via a single dose. The technology could eliminate the need for separate basal and prandial insulin injections and profoundly improve the standard of care for type 1 and type 2 diabetes patients.
“The goal of our technology is to give those with diabetes a chance at a normal life,” said Mike Moradi, Sensulin’s co-founder and CEO. “I have a vast family history of diabetes and this technology is particularly important to me.”